ANI Pharmaceuticals ANIP Finished goods
Finished goods at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryFinishedGoods.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's finished goods.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is ANI Pharmaceuticals's finished goods?
- ANI Pharmaceuticals (ANIP) reported finished goods of $54.85M in Q1 2026.
- How has ANI Pharmaceuticals's finished goods changed year-over-year?
- ANI Pharmaceuticals's finished goods decreased by 8.6% year-over-year, from $59.98M to $54.85M.
- What is the long-term trend for ANI Pharmaceuticals's finished goods?
- Over 3 years (2022 to 2025), ANI Pharmaceuticals's finished goods has grown at a 26.0% compound annual growth rate (CAGR), from $28.02M to $55.99M.
- What does finished goods mean?
- Completed products ready for sale, valued at the lower of cost or net realizable value.